Leonhardt Ventures
  • Home
  • About
    • About us
    • 2021 Top Achievements
    • Leonhardt Ventures Portfolio Clinical Trials Listing
    • Founder Bio
    • Development Pipeline
    • Regenerative Medtech
    • Media
      • Company Logos
    • LV Team
      • Board of Directors
      • Team
      • Accelerator Core Team
      • Portfolio Startups Boards
      • Scientific Advisory Board
  • Our Startups
  • News
  • Investors
    • Invest in us
    • Agreements & Forms
      • Agreement Forms
      • Master Patent IP License and Development Agreement
      • Accelerator Membership Agreement
      • Term Sheet
      • 409a Valuation Accelerator
      • Simple Agreement for Future Equity
        • Simple Agreement for Future Equity – Word
        • Simple Agreement for Future Equity – PDF
    • Leonhardts Launchpads
      • Leonhardt’s Launchpads Valuations
      • Accelerator Business Model
      • Cap Tables and Valuations
    • Important
      • 2022 Budget
      • 2022 Compared YTD Budget
      • Legal Terms Summary
      • Executive Chairman’s 2022 Update
      • Board Governance
      • 2023 Goals
      • Current Clinical Trials
      • Executive Summary
    • Clinical Studies
      • Clinical Study Enrollment 10/1/19
    • Investor FAQ
    • Leonhardt Ventures LLC Patent Licenses 2022
    • Annual Reports
      • 2022 Annual Report Executive Summary
      • 2016-2022
        • Mid-Year 2022 Semi-Annual Report
        • 2021 Annual Report
        • 2020 Annual Report
        • 2019 Annual Report
        • 2018 Annual Report
        • 2017 Annual Report
        • 2016 Annual Report
      • 2012-2015
        • 2015/16 Annual report
        • 1Q 2015 Newsletter
        • 2013/14 Annual Newsletter
        • 2012 Fall Newsletter
  • Contact
Select Page
DepressiStim Announces Clinical Trial Progress

DepressiStim Announces Clinical Trial Progress

by hleonhardt | Mar 6, 2023 | Brain, News

DepressiStim TM Reports Progress on Treatment Resistant Depression Pilot Clinical Study  The DepressiStim TM Brain Band therapy system is intended to be indicated for adjunctive non-invasive treatment of chronic or recurrent depression in patients who are experiencing...

Recent Posts

  • Second Heart Assist, Inc. Announces Issuance of 20 New U.S. Patent Claims Covering its Circulatory Assist Device Technology Platform
  • DepressiStim Announces Clinical Trial Progress
  • Leonhardt Ventures Lands 12th Issued Patent for Bioelectric Treatment of Cancers – OPG Control
  • Leonhardt Ventures and Lionheart Health Announce Patent Application Filing for Bioelectric Control of SESTRINs Anti-Aging Protein Expressions
  • TremorStim Unveils 2nd Generation Combination Head and Wrist Band Bioelectric Device for Treatment of Essential Tremor
  • Facebook
  • Twitter
© Copyright Leonhardt Ventures | Website by FizzPOP Media
Cleantalk Pixel